Sarepta Therapeutics, Inc. revenue
Sarepta Therapeutics, Inc.'s revenue was $2.20bn in fiscal 2025, up 15.6% on the year before. Since fiscal 2014 ($9.8m) it has grown at a compound 63.6% a year. Over the last twelve months it was $1.97bn.
Revenue history
| Fiscal year | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 1 | 5 | 155 | 301 | 381 | 540 | 702 | 933 | 1,243 | 1,902 | 2,198 | 1,974 |
| Growth on the year before | — | −87.2% | +332.6% | +>999% | +94.7% | +26.5% | +41.8% | +30.0% | +32.9% | +33.3% | +53.0% | +15.6% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | 2,173 | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 98.8% | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Pmo Products | $966M | ▼ 0.2% |
| Elevidys | $899M | ▲ 9.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Sarepta Therapeutics, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $1.97bn | -20.4% | 25.3% |
| Moderna | $2.23bn | -27.6% | -40.6% |
| Alkermes plc. | $1.67bn | 10.8% | 4.5% |
| Halozyme Therapeutics, Inc. | $1.66bn | 41.2% | 29.1% |
| Exelixis, Inc. | $2.50bn | 9.1% | 12.1% |
| Insmed Inc | $1.52bn | 240.0% | 75.6% |
Compare with peers
- Moderna revenue
- Alkermes plc. revenue
- Halozyme Therapeutics, Inc. revenue
- Exelixis, Inc. revenue
- Insmed Inc revenue
Head to head: MRNA vs SRPTALKS vs SRPTHALO vs SRPT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies